Glylim Forte Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, formulated to manage type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, enhances pancreatic insulin secretion, thereby lowering blood glucose levels. Metformin, a biguanide, improves insulin sensitivity and decreases hepatic glucose production, contributing to better glycemic control. This sustained-release formulation ensures a gradual release of active ingredients, promoting consistent plasma concentrations and reducing gastrointestinal side effects commonly associated with immediate-release metformin. Glylim Forte Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes when monotherapy with either agent is inadequate. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia or lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and rarely, lactic acidosis. Patient education on adherence, lifestyle modifications, and recognition of hypoglycemia symptoms is crucial for optimal management. Glylim Forte Tablet SR should be prescribed and used under medical supervision with periodic assessment of renal function and glycemic parameters.